NASDAQ:PROK ProKidney Q2 2024 Earnings Report $1.70 -0.05 (-2.57%) As of 02:40 PM Eastern ProfileEarnings HistoryForecast ProKidney EPS ResultsActual EPS-$0.16Consensus EPS -$0.17Beat/MissBeat by +$0.01One Year Ago EPSN/AProKidney Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AProKidney Announcement DetailsQuarterQ2 2024Date8/9/2024TimeBefore Market OpensConference Call DateFriday, August 9, 2024Conference Call Time7:00AM ETUpcoming EarningsProKidney's Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) ProKidney Earnings HeadlinesFY2030 EPS Estimates for ProKidney Lowered by HC WainwrightMay 20, 2026 | americanbankingnews.comProKidney (NASDAQ:PROK) Receives "Buy" Rating from HC WainwrightMay 19, 2026 | americanbankingnews.comMusk's shopping list: batteries ✓ solar ✓ data ✓ power ___Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity for $2.6 billion and Twitter for $44 billion. Now one small company makes the equipment his Colossus supercomputer - a million GPUs consuming nearly $1 billion a month in power - cannot run without. Analyst Dylan Jovine has identified the name and ticker. For investors who own shares before a potential move, the math could be significant.May 26 at 1:00 AM | Behind the Markets (Ad)ProKidney (NASDAQ:PROK) Stock Rating Lowered by Wall Street ZenMay 16, 2026 | americanbankingnews.comProKidney Corp. Reports Phase 3 PROACT 1 Study Enrollment Progress and Q1 2026 Financial ResultsMay 15, 2026 | quiverquant.comQProKidney Reports First Quarter 2026 Financial Results and Business HighlightsMay 15, 2026 | globenewswire.comSee More ProKidney Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ProKidney? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProKidney and other key companies, straight to your email. Email Address About ProKidneyProKidney (NASDAQ:PROK), Inc. (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options. ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products. These candidates are designed to mitigate inflammatory responses, promote tissue repair and reduce the progression of kidney damage in hospitalized patients at risk of AKI, including those undergoing major surgery or experiencing sepsis. In addition to its clinical-stage portfolio, the company maintains preclinical efforts exploring broader applications in CKD and related nephrology indications. Founded in 2015 and headquartered in Massachusetts, ProKidney completed its initial public offering in 2022, trading on the NASDAQ under the ticker PROK. The management team comprises professionals with expertise in nephrology research, cell therapy manufacturing and clinical development. ProKidney conducts its clinical trials predominantly in the United States, collaborating with academic medical centers and specialized contract research organizations to advance its pipeline toward regulatory milestones. View ProKidney ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AutoZone's Pullback Sets Up a Long-Term Buying OpportunityAST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in FocusPowerhouse Williams-Sonoma Heading to Fresh Highs in 2026Why BJ’s Wholesale Club Stock Could Be Ready for a ReboundRocket Companies Turns Around, But Mortgage Risk RemainsAfter NVIDIA, Broadcom's Earnings Are Next—Here's What to WatchRoss Stores Earnings Beat Sends Stock To New Highs Upcoming Earnings Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026)Canadian Imperial Bank of Commerce (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
